Nayak L, Molinaro AM, Peters KB, Clarke JL, et al. Randomized phase II and biomarker study of pembrolizumab plus bevacizumab versus pembrolizumab alone for recurrent glioblastoma patients. Clin Cancer Res 2020 Nov 16. pii: 1078-0432.CCR-20-2500.
PMID: 33199490